4.5 Article

Comorbidity Patterns of Anxiety and Depressive Disorders in a Large Cohort Study: the Netherlands Study of Depression and Anxiety (NESDA)

Journal

JOURNAL OF CLINICAL PSYCHIATRY
Volume 72, Issue 3, Pages 341-348

Publisher

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.10m06176blu

Keywords

-

Funding

  1. Netherlands Organisation for Health Research and Development [10-000-1002]
  2. European Union
  3. Stanley Medical Research Institute
  4. AstraZeneca
  5. Eli Lilly
  6. GlaxoSmithKline
  7. Wyeth
  8. Servier
  9. Pfizer
  10. VU University Medical Center
  11. GGZ inGeest
  12. Arkin
  13. Leiden University Medical Center
  14. GGZ Rivierduinen
  15. University Medical Center Groningen
  16. Lentis
  17. GGZ Friesland
  18. GGZ Drenthe
  19. Scientific Institute for Quality of Healthcare (IQ Healthcare)
  20. Netherlands Institute for Health Services Research (NIVEL)
  21. Netherlands Institute of Mental Health and Addiction (Trimbos)

Ask authors/readers for more resources

Background: Comorbidity of depressive and anxiety disorders is common and has been shown to be a consistent predictor of chronicity. Comorbidity patterns among specific depressive and anxiety disorders have not been extensively reported. This study examines comorbidity patterns and temporal sequencing of separate depressive and anxiety disorders using data from a large psychiatric cohort. Method: Baseline data (N = 1,783) of the Netherlands Study of Depression and Anxiety, collected between September 2004 and February 2007, were used. Current and lifetime comorbidity rates for depressive and anxiety disorders (DSM-IV-TR criteria) were calculated. Associations of comorbidity with sociodemographic, vulnerability, and clinical characteristics, and temporal sequencing of disorders were examined. Results: Of those with a depressive disorder, 67% had a current and 75% had a lifetime comorbid anxiety disorder. Of persons with a current anxiety disorder, 63% had a current and 81% had a lifetime depressive disorder. Comorbidity of depressive and anxiety disorders was associated with more childhood trauma (OR = 1.19; 95% CI, 1.06-1.33), higher neuroticism (OR = 1.05; 95% CI, 1.02-1.08), earlier age at onset of first disorder (OR = 1.59; 95% CI, 1.22-2.07), longer duration of depressive and/or anxiety symptoms (OR = 1.01; 95% CI, 1.01-1.01), and higher symptom severity (ORs ranging from 1.01 to 1.03; all P values < .05). In 57% of comorbid cases, anxiety preceded depression, and in 18%, depression preceded anxiety. Comorbidity with preceding depression compared to preceding anxiety was associated with a shorter duration of symptoms of depressive and/or anxiety symptoms (OR = 0.99; 95% CI, 0.98-0.99), earlier age at first onset (OR = 0.46; 95% CI, 0.31-0.68), and fewer fear symptoms (OR = 0.98; 95% CI, 0.97-0.99). Conclusions: Comorbidity rates in anxiety and depressive disorders were very high, indicating that it is advisable to assess both disorders routinely regardless of the primary reason for consultation. This is especially important since comorbid patients showed a specific vulnerability pattern, with more childhood trauma, neuroticism, and higher severity and duration of symptoms. J Clin Psychiatry 2011;72(3):341-348 (C) Copyright 2011 Physicians Postgraduate Press, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available